Haemonetics to acquire OpSens for more than $250M

Boston, MA, October 10, 2023 (PRNewswire) -- Haemonetics (NYSE: HAE) has announced an agreement for the acquisition of OpSens, a technology company specializing in cardiology. Based in Boston, Haemonetics will purchase all the outstanding shares of OpSens at a price of CAD $2.90 per share in an all-cash deal. The transaction is anticipated to be completed by the end of January 2024.

Read full article here.